Compounds > fusaristatin a
Page last updated: 2024-11-13

fusaristatin a

Description

fusaristatin A: an antineoplastic antibiotic isolated from Fusarium; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID76327984
CHEMBL ID3086839
MeSH IDM0513046

Synonyms (2)

Synonym
CHEMBL3086839
fusaristatin a
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1055421Antibacterial activity against multidrug and methicillin-resistant Staphylococcus aureus 25697 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055423Antibacterial activity against Bacillus subtilis 168 trpC2 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055422Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055420Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055417Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa B 63230 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055419Antibacterial activity against multidrug and vancomycin-resistant Enterococcus faecalis UW 2689 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
AID1055418Antibacterial activity against Escherichia coli ATCC 25922 assessed as growth inhibition by broth microdilution method2013Journal of natural products, Nov-22, Volume: 76, Issue:11
Inducing secondary metabolite production by the endophytic fungus Fusarium tricinctum through coculture with Bacillus subtilis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.25 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0810aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.0810glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
n-(2-carboxyphenyl)glycine
[no description available]		2.0810
enniatin b
enniatins: cyclohexadepsipeptides containing valine, isoleucine & valeric acid from Fusarian; form complexes with cations & cellular membranes; there are at least three different enniatins H, B & C; minor descriptor (76-86); on-line & INDEX MEDICUS search PEPTIDES, CYCLIC (76-86); see also record for enniatin D, E, F. enniatin B : An enniatin obtained from formal cyclocondensation of three N-[(2R)-2-hydroxy-3-methylbutanoyl]-N-methyl-L-valine units.		2.0810enniatinantimicrobial agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Acinar Carcinoma
[description not available]		02.0610
Invasiveness, Neoplasm
[description not available]		02.0610
Carcinoma, Acinar Cell
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)		02.0610
chemdatabank.com